Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine
kinase, has served as a paradigm for successful application of molecularly targeted cancer …

Chronic myeloid leukemia (CML) is caused by the acquisition of the tyrosine kinase BCR-
ABL1 in a hemopoietic stem cell, transforming it into a leukemic stem cell (LSC) that self …

Simple Summary Cancer is one of the hardest pathologies to fight, being one of the main
causes of death worldwide despite the constant development of novel therapeutic strategies …

The development of oncoprotein-targeted anticancer drugs is an invaluable weapon in the
war against cancer. However, cancers do not give up without a fight. They may develop …

Aberrant activation of the JAK/STAT pathway has been reported in a variety of disease
states, including inflammatory conditions, hematologic malignancies, and solid tumors. For …

Every year, more than 8000 new cases of chronic myeloid leukemia (CML) are diagnosed in
the United States. 1 BCR-ABL1, a fusion protein kinase derived from a reciprocal …

Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …

Tyrosine kinase inhibitors (TKIs) are highly effective in treatment of chronic myeloid
leukemia (CML) but do not eliminate leukemia stem cells (LSCs), which remain a potential …

Abl kinases are prototypic cytoplasmic tyrosine kinases and are involved in a variety of
chromosomal aberrations in different cancers. This causes the expression of Abl fusion …

Chronic myeloid leukemia (CML) stem cell survival is not dependent on BCR-ABL protein
kinase and treatment with ABL tyrosine kinase inhibitors cures only a minority of CML …